Compare ADMA Biologics Inc (ADMA) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs NEOS S&P 500 High Income ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while NEOS S&P 500 High Income ETF trades at $53.11. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SPYI | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $54.07 |
52-Week Low | $7.60 | $47.98 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SPYI trades at $53.45, up 0.74% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has surpassed $10 billion in assets under management, driven by strong demand for its covered-call strategy that delivers an 11.86% yield. Recent dividends of $0.52-$0.54 per share highlight its income focus, though key valuation ratios like P/E and P/B are not applicable for this ETF structure.
Outlook remains positive due to robust investor inflows and competitive yield advantages over peers like JEPI. Risks include high fees impacting long-term returns and potential volatility from its options strategy. The fund's tax-efficient distributions appeal to retirees, but reliance on return of capital requires careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
